Amendments to the Claims:

This listing of claims will replace all prior version, and listings, of claims in the application.

Listing of Claims:

Claims 1-3 (cancelled)

Claims 4-15 (previously cancelled)

Claim 16 (cancelled)

Claims 17-32 (previously cancelled)

Claims 33-35 (cancelled)

Claims 36-42 (previously cancelled)

Claim 43 (cancelled)

Claims 44-52 (previously cancelled)

Claims 53-63 (cancelled)

Claim 64. (New) A compound having the structure:



;

wherein R_1 is independently H, F, Cl, Br, -CN, -OH, $-NO_2$, $-NR_5R_6$, $-SO_2R_5$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nNR_5COR_5$, perfluoroalkyl, polyfluoroalkyl, aminoalkyl, or straight chained or branched C_1-C_7 alkyl;

wherein R_5 is independently H; or straight chained or branched C_1-C_7 alkyl;

wherein R_6 is independently H; or straight chained or branched C_1-C_7 alkyl;

wherein each n independently is an integer from 0 to 6 inclusive;

wherein R_7 is independently straight chained or branched C_1-C_7 alkyl;

wherein R_8 is



;

wherein R_9 is independently H; or straight chained or branched C_1-C_4 alkyl;

wherein R_{10} is independently H; or straight chained or branched C_1-C_4 alkyl;

wherein R_{11} is



;

wherein R_{12} is H, straight chained or branched C_1-C_7 alkyl, $-(CH_2)_uOR_{17}$, or $-O(CH_2)_uOR_{17}$;

wherein R_{13} is independently H; $-(CH_2)_uOR_5$; $-(CH_2)_tCONR_5R_6$; $-(CH_2)_uNR_5COR_5$; $-(CH_2)_tCOR_7$; $-(CH_2)_tCO_2R_5$; $-(CH_2)_uNR_5R_6$; $-(CH_2)_uCN$; straight chained or branched C_1-C_7 alkyl; C_1-C_7 alkyl in which the C_2-C_7 atoms may be optionally substituted with one or more F or Cl; C_3-C_7 cycloalkyl-C_1-C_7 alkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; or C_3-C_7 cycloalkyl; phenyl or C_1-C_6 phenylalkyl; wherein the phenyl or C_1-C_6 phenylalkyl may be

substituted with one or more of F, Cl, -CN, $-NO_2$, $-NR_5R_6$, $-SO_2R_5$, $-(CH_2)_nCOR_7$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nNR_5COR_5$, $-(CH_2)_nCO_2R_5$, $-(CH_2)_nSO_2NR_5R_6$, straight chained or branched C_1-C_7 alkyl, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl;

or R_{12} and R_{13} together with the amide linkage to which they are attached are pyrrolidinonyl, piperidonyl or oxazolidinonyl;

wherein R_{14} is H; straight chained or branched C_1-C_4 alkyl; F; or $-(CH_2)_rOR_5$;

wherein R_{15} is H, straight chained or branched C_1-C_4 alkyl, or F;

with the proviso that when R_{14} is -OH, R_{15} cannot be F;

wherein R_{16} is perfluoroalkyl, unsubstituted straight chained or branched C_1-C_7 alkyl, substituted straight chained or branched C_2-C_7 alkyl, wherein the C_2-C_7 alkyl may be substituted with one or more of F, Cl, -CN, $-SO_2R_5$, $-(CH_2)_nCOR_7$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nNR_5COR_5$, $-(CH_2)_nCO_2R_5$, $-(CH_2)_nOCF_3$, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl, straight chained or branched C_2-C_7 alkenyl or alkynyl, or C_3-C_7 cycloalkyl or cycloalkenyl; phenyl, heteroaryl, or C_1-C_7 phenylalkyl, wherein the phenyl, heteroaryl, or C_1-C_7 phenylalkyl may be substituted with one or more of F, Cl, Br, -CN, $-NO_2$, $-NR_5R_6$, $-(CH_2)_nNR_5COR_5$, $-SO_2R_5$, $-(CH_2)_nCOR_7$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nCO_2R_5$, $-(CH_2)_nSO_2NR_5R_6$, ethylenedioxy, methylenedioxy, straight chained or branched C_1-C_7 alkyl, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl, straight chained or branched C_2-C_7 alkenyl or alkynyl, or C_3-C_7 cycloalkyl or cycloalkenyl; quinolinyl, 1-napthyl, 2-napthyl, or 2,1,3-benzothiadiazolyl; wherein the quinolinyl, 1-napthyl, 2-napthyl, or 2,1,3-benzothiadiazolyl may be substituted with one or more of F, Cl, Br, -CN, $-NO_2$, $-NR_5R_6$, $-(CH_2)_nNR_5COR_5$, $-SO_2R_5$, $-(CH_2)_nCOR_7$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nCO_2R_5$, $-(CH_2)_nSO_2NR_5R_6$,

ethylenedioxy, methylenedioxy, straight chained or branched C_1-C_7 alkyl, perfluoroalkyl, polyfluoroalkyl, or aminoalkyl;

with the proviso that when R_8 is $NR_9(R_{14}R_{15})_sNR_{10}R_{11}$, R_{16} cannot be quinolinyl;

wherein R_{17} is H, straight chained or branched C_1-C_4 alkyl, perfluoroalkyl, or polyfluoroalkyl;

wherein each p independently is an integer from 0 to 2 inclusive;

wherein each r independently is an integer from 0 to 3 inclusive;

wherein each s independently is an integer from 1 to 6 inclusive;

wherein t is an integer from 1 to 4 inclusive; and

wherein each u independently is an integer from 2 to 4 inclusive;

or a pharmaceutically acceptable salt thereof.

65. (New) The compound of claim 64, wherein R_1 is independently H, F, Cl or Br;

wherein R_{16} is unsubstituted straight chained or branched C_1-C_7 alkyl, phenyl, heteroaryl, or C_1-C_7 phenylalkyl, wherein the phenyl, heteroaryl, or C_1-C_7 phenylalkyl may be substituted with one or more of F, Cl, Br, -CN, $-NO_2$, $-NR_5R_6$, $-(CH_2)_nNR_5COR_5$, $-SO_2R_5$, $-(CH_2)_nCOR_7$, $-(CH_2)_nOR_5$, $-(CH_2)_nCONR_5R_6$, $-(CH_2)_nCO_2R_5$ and $-(CH_2)_nSO_2NR_5R_6$; and p is 1.

66. (New) The compound of claim 65, wherein R_8 is



67. (New) The compound of claim 66, wherein the compound is



68. (New) The compound of claim 65, wherein R_8 is



69. (New) The compound of claim 68, wherein the compound is selected from the group consisting of:



70. (New) The compound of claim 65, wherein R_8 is



71. (New) The compound of claim 70, wherein the compound is selected from the group consisting of:



72. (New) The compound of claim 64, wherein the compound is the (+) enantiomer.

73. (New) The compound of claim 64, wherein the compound is the (-) enantiomer.

74. (New) A pharmaceutical composition comprising a

therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

75. (New) The pharmaceutical composition of claim 64, wherein the amount of the compound is an amount from about 0.01mg to about 800mg.

76. (New) The pharmaceutical composition of claim 75, wherein the amount of the compound is an amount from about 0.01mg to about 500mg.

77. (New) The pharmaceutical composition of claim 76, wherein the amount of the compound is an amount from about 0.01mg to about 250mg.

78. (New) The pharmaceutical composition of claim 77, wherein the amount of the compound is an amount from about 0.1mg to about 60mg.

79. (New) The pharmaceutical composition of claim 78, wherein the amount of the compound is an amount from about 1mg to about 20mg.

80. (New) The pharmaceutical composition of claim 74, wherein the carrier is a liquid and the composition is a solution.

81. (New) The pharmaceutical composition of claim 74, wherein the carrier is a solid and the composition is a tablet.

82. (New) The pharmaceutical composition of claim 74, wherein the carrier is a gel and the composition is a suppository.

83. (New) A pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

84. (New) A process for making a pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 64 and a pharmaceutically acceptable carrier.

85. (New) Use of the compound of claim 64 for the preparation of a pharmaceutical composition for treating obesity.

86. (New) Use of the compound of claim 64 for the preparation of a pharmaceutical composition for treating depression.

87. (New) Use of the compound of claim 64 for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

88. (New) Use of the compound of claim 64, wherein the abnormality is an eating disorder, obesity, bulimia nervosa, a sexual disorder, a reproductive disorder, depression, an epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, or a sleep disturbance.